Entry Rationale
Given the strong performance momentum indicated by the earnings surprise and upward guidance, I will consider entering based on the potential for a breakout above the resistance level.
Bausch Health Companies Non-GAAP EPS of $1.26 beats by $0.25, revenue of $2.85B beats by $190M
Bausch Health Companies reported second-quarter results that exceeded expectations, and guidance was raised, marking the 13th consecutive quarter of growth.
Given the strong performance momentum indicated by the earnings surprise and upward guidance, I will consider entering based on the potential for a breakout above the resistance level.
If the positive performance indicators and the trend of breaking through the resistance level of 4.90 continue, it is expected to reach the profit-taking target of $5.1. In the event that it falls below the support level of 4.50 or if additional downside risks materialize, we will respond with a stop-loss at $4.4.
The current RSI(14) is 42.9, which is not in the overbought range; however, one must consider both the potential for a breakout above resistance due to positive earnings news and the risk of a drop below the support level.
Past similar success cases include stock BHC (2026-07-31, return of 28.8% and 28.7%, related performance and guidance upgrade news) and stock THC (2026-07-31, return of 27.0%, earnings surprise news).
The actual results (28.7%) significantly exceeded the forecasted return (3.5%) due to the performance momentum being much stronger than expected and the previous day's surge not being fully reflected, resulting in an OVERHIT designation.
When encountering stocks with strong performance catalysts and earnings surprises, I will reflect in the next trade a more aggressive trust in the continuity of the previous trading day's surge and upward guidance, beyond simple short-term resistance levels, by flexibly adjusting the profit-taking target.